Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2671 to 2685 of 9090 results

  1. Ibrutinib with R-CHOP for untreated mantle cell lymphoma when an autologous stem cell transplant is suitable [ID6596]

    In development Reference number: GID-TA11802 Expected publication date: TBC

    Technology appraisal guidance
    In development

  2. Trastuzumab deruxtecan for neoadjuvant treatment of HER2-positive early breast cancer [ID6620]

    Awaiting development Reference number: GID-TA11403 Expected publication date:  27 May 2027

    Technology appraisal guidance
    Awaiting development

  3. Miniature lens system implantation for advanced age-related macular degeneration

    In development Reference number: GID-HTG10468 Expected publication date: TBC

    HealthTech guidance
    In development

  4. Frailty: identification and assessment in adults

    Awaiting development Reference number: GID-NG10555 Expected publication date: TBC

    NICE guideline
    Awaiting development

  5. Polyendocrine Metabolic Ovarian Syndrome (PMOS): draft guidance

    We are listening to your views on this NICE guideline. Comments close 11 August 2026.

    NICE guideline
    In consultation

  6. Ciltacabtagene autoleucel for treating relapsed and lenalidomide-refractory multiple myeloma after 1 to 3 therapies [D5]

    Deferred Reference number: GID-TA10905

    Technology appraisal guidance
    Deferred

  7. Polyendocrine Metabolic Ovarian Syndrome (PMOS)

    In development Reference number: GID-NG10436 Expected publication date:  09 December 2026

    NICE guideline
    In development

  8. Ciltacabtagene autoleucel for treating relapsed and lenalidomide-refractory multiple myeloma after 1 to 3 therapies (deferred appraisal of D5) [GID-TA12518]

    Awaiting development Reference number: GID-TA12518 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  9. Pirtobrutinib for treating relapsed or refractory mantle cell lymphoma untreated with a BTK inhibitor [ID6493]

    Awaiting development Reference number: GID-TA11639 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  10. Familial Breast Cancer: initial assessment and genetic testing (update)

    In development Reference number: GID-NG10438 Expected publication date:  22 April 2027

    NICE guideline
    In development

  11. Topical tapinarof for treating atopic dermatitis in people 2 years and over ID6713: consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

    We are listening to your views on this Technology appraisal guidance. Comments close 1 July 2026.

    Technology appraisal guidance
    In consultation

  12. Bladder cancer: diagnosis and management (update)

    In development Reference number: GID-NG10452 Expected publication date: TBC

    NICE guideline
    In development

  13. Novel risk profiling technologies to guide adjuvant chemotherapy decisions in early breast cancer

    Awaiting development Reference number: GID-HTG10904 Expected publication date: TBC

    HealthTech guidance
    Awaiting development

  14. Mezigdomide with dexamethasone and carfilzomib for treating relapsed or refractory multiple myeloma after at least 1 line of treatment ID6513: consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

    We are listening to your views on this Technology appraisal guidance. Comments close 29 June 2026.

    Technology appraisal guidance
    In consultation

  15. Mezigdomide with dexamethasone and carfilzomib for treating relapsed or refractory multiple myeloma after at least 1 line of treatment ID6513

    Awaiting development Reference number: GID-TA11660 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development